Jump to content
Content on WikiMesothelioma is reviewed prior to publication by three named attorneys at Danziger & De Llano LLP. Dr. Luciano Mutti, MD, PhD, co-author of the European mesothelioma treatment guidelines, serves as the site's Medical Reviewer. See our editorial standards.

Mesothelioma Symptoms

From WikiMesothelioma — Mesothelioma Knowledge Base
Mesothelioma Symptoms
Most Common Type Pleural (81% of U.S. cases, 2003-2022)
Most Common Symptom Breathlessness (dyspnea)
Time to Diagnosis Varies widely by health system
Misdiagnosis Rate No reliable estimate
Median Survival About 8-12 months from diagnosis (population data)
Stage at Diagnosis Most patients diagnosed at an advanced stage
Latency Period Several decades after first asbestos exposure (96% at least 20 years; median at least 32 years)[1]
Phone (855) 699-5441
Free Case Review →

Executive Summary

Mesothelioma symptoms are notoriously nonspecific, and published measurements of the time from first symptoms to diagnosis are limited and vary widely by health system. In one Brazilian tertiary-centre study of 66 patients (2009-2020), the median time from symptom onset to first specialist visit was 6.5 months, and from specialist visit to histological diagnosis 1.5 months.[2] In the United States, about 8 to 9 in 10 mesotheliomas arise in the pleura (81% of cases in national registry data for 2003-2022) and about 1 in 10 in the peritoneum (11%), while pericardial and tunica vaginalis (testicular) mesothelioma each account for about 0.2%.[3] The split depends on the registry, era and sex; peritoneal disease is a larger share of cases among women (20.5%) than among men (8.1%).[3] Age-standardized U.S. incidence fell 33% (from 0.64 to 0.43 per 100,000) and mortality 31% between 1990 and 2023, with much steeper declines among men than women, while the absolute numbers of cases and deaths rose.[4] Pleural mesothelioma most often presents with shortness of breath, chest pain and pleural effusion, which were present in 59%, 53% and 86% of patients in a single-centre Spanish series of 70 patients (2008-2021).[5][6] Peritoneal mesothelioma presents with abdominal symptoms, most often ascites and abdominal pain.[7][8] No study has established how often mesothelioma is clinically mislabelled (for example as pneumonia, COPD or lung cancer) before a biopsy is taken. In France's national surveillance programme, expert-panel review confirmed the initial pathologist's diagnosis in 67% of cases and ruled it out in 13%.[9] Histological cell type substantially affects prognosis; epithelioid mesothelioma is the most common subtype, and the proportions of epithelioid, sarcomatoid and biphasic disease vary with the registry, era and stage.[10][11] Among 1,183 patients with stage I-III pleural mesothelioma in SEER (2004-2010), 69% were epithelioid, 12% biphasic and 19% sarcomatoid.[12] Blood, breath and DNA-based biomarker tests for mesothelioma, such as micro-RNAs and mesothelin in blood and volatile organic compounds in breath, are being studied in research cohorts that need further validation.[13][14] None has been validated for screening or early detection in people with past asbestos exposure, and no screening tool is currently advocated.[15] Prompt medical evaluation of unexplained respiratory or abdominal symptoms, especially with a history of asbestos exposure, allows timely diagnosis and referral to specialists; acting early also matters for preserving legal claims.

At a Glance

Mesothelioma symptoms at a glance:

  • Most common symptoms — in a single-centre Spanish series of 70 patients with pleural mesothelioma, dyspnea (59%) and chest pain (53%) were the most common symptoms at diagnosis[6]
  • Fluid around the lung — pleural effusion was present in 86% of the same 70 patients at diagnosis[6]
  • Where it starts — 81% of U.S. mesotheliomas diagnosed in 2003-2022 arose in the pleura and 11% in the peritoneum[3]
  • Peritoneal symptoms — ascites (abdominal fluid), abdominal pain, weakness, weight loss, loss of appetite and an abdominal mass, in various combinations[16]
  • Testicular presentation — in a review of 289 published cases, scrotal or testicular swelling or mass (65%) and hydrocele (55%) were the most common presentations[17]
  • Long latency — in a pooled review of 1,105 occupational cases, 96% had a latent period of at least 20 years after first asbestos exposure[1]
  • Stage at diagnosis — many cases are diagnosed at an advanced stage, and there are no validated screening strategies[18]
  • Time to diagnosis — in one Brazilian study of 66 patients, the median time from symptom onset to first specialist visit was 6.5 months[2]
  • Treatment for advanced disease — in CheckMate 743, first-line nivolumab plus ipilimumab improved median overall survival versus chemotherapy (18.1 vs 14.1 months) in unresectable pleural mesothelioma[19]; these are medians in a selected trial population, not predictions for an individual

Key Facts

Key Facts: Mesothelioma Symptoms and Diagnosis
  • Pleural Mesothelioma (81% of U.S. cases): In a single-centre Spanish series of 70 patients, the most common symptoms were dyspnea (59%), chest pain (53%) and cough (37%), and pleural effusion was present in 86% at diagnosis[6][3]
  • Peritoneal Mesothelioma (about 1 in 10 U.S. cases): Presenting symptoms include ascites, abdominal pain, asthenia (weakness), weight loss, anorexia and an abdominal mass, in various combinations[16]
  • Pericardial Mesothelioma (about 0.2% of U.S. cases): Very rare; the most common clinical presentation was pericardial effusion, and median overall survival was 2.8 months, in Italy's national registry (72 cases)[20]
  • Testicular Mesothelioma (about 0.2% of U.S. cases): Often discovered during scrotal surgery. In a review of 289 published cases, the most common presentations were scrotal or testicular swelling or mass (65%) and hydrocele (55%)[17]
  • Epithelioid Mesothelioma (most common subtype): Least aggressive; typically presents with a dyspnea-dominant symptom profile. Median survival 14 months in SEER stage I-III pleural mesothelioma (2004-2010)[12]
  • Sarcomatoid Mesothelioma (19% in the same SEER cohort): Most aggressive; median survival 4 months in SEER stage I-III pleural mesothelioma (2004-2010)[12]
  • Time to Diagnosis: Published measurements are limited and vary by health system; in one Brazilian study of 66 patients, the median time from symptom onset to first specialist visit was 6.5 months[2]
  • Stage at Diagnosis: Many cases are diagnosed at an advanced stage, and there are no validated screening strategies[18]
  • Misdiagnosis: No reliable estimate of clinical misdiagnosis exists; expert pathology review in France's national surveillance programme confirmed 67% of initial diagnoses and ruled out 13%[9]
  • Symptom Progression: Early disease presents with subtle symptoms; advanced stage involves severe dyspnea, refractory pain, weight loss, and constitutional symptoms
  • Latency Period: Mesothelioma typically appears decades after first asbestos exposure: in a pooled review of 1,105 occupational cases, 96% had a latent period of at least 20 years, and the estimated median latent period was at least 32 years[1]
  • Survival: Median overall survival from diagnosis was 10.3 months among 41,074 patients in the U.S. National Cancer Database (2004-2020)[21]. In SEER data for pleural mesothelioma diagnosed 2015-2021, 5-year relative survival was 23% for localized, 15% for regional and 11% for distant disease; these are population figures, not predictions for an individual[22]

What Are the Most Common Symptoms of Pleural Mesothelioma?

Pleural mesothelioma is the most common form, arising from the membrane lining the lungs. A single-centre Spanish series of 70 patients with pleural mesothelioma (2008-2021) reported the symptoms present at diagnosis.[5][6]

Early-Stage Pleural Symptoms (Stage I-II)

In localized disease, symptoms are often subtle and mimic benign respiratory conditions:

  • Dyspnea (Shortness of Breath) — 59% in the Spanish series: Usually the first symptom, related to pleural effusion restricting lung expansion. Patients often attribute this to aging or occupational lung disease. Severity typically increases gradually over weeks to months. Progressive dyspnea in older patients with asbestos exposure history is frequently misattributed to COPD or heart disease.[23]
  • Chest Pain — 53% in the Spanish series: Dull, persistent, or pleuritic (sharp with breathing). May be localized to the affected side or diffuse. Pain stems from pleural invasion and tumor growth along the chest wall. Early chest pain may be attributed to muscle strain or heart disease.
  • Cough — 37% in the Spanish series: Typically dry and non-productive. Often persistent and unresponsive to standard cough suppressants or antibiotics. May worsen with deep breathing or coughing due to pleural irritation. Coughing up blood (hemoptysis) is uncommon.
  • Weight Loss — 23% at diagnosis in the Spanish series: Usually subtle in early disease; becomes more pronounced as disease advances. Underlying mechanisms include systemic inflammation, cachexia from tumor burden, and reduced nutritional intake.
  • Pleural Effusion — 86% in the Spanish series: Present on imaging in most cases at diagnosis. Effusion is often the radiographic finding that prompts further investigation, even when clinical symptoms are nonspecific. Large pleural effusions with ipsilateral lung collapse present significant diagnostic and prognostic challenges.
ℹ Critical Finding: Pleural effusion (fluid around the lungs) was present in 86% of pleural mesothelioma cases at diagnosis in the Spanish series. This finding, combined with respiratory symptoms in a person with past asbestos exposure, warrants prompt evaluation, including imaging and, where indicated, biopsy. Performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine mesothelioma management.[24]

Advanced Pleural Symptoms (Stage III-IV)

As mesothelioma progresses, symptoms become severe and debilitating:

  • Worsening Dyspnea: Trapped lung from visceral pleural thickening makes breathing increasingly difficult, often becoming severe at rest. Recurrent effusions requiring therapeutic drainage for symptomatic relief.
  • Severe Refractory Chest Pain: Pain from chest wall invasion and intercostal nerve involvement; requires escalating opioid analgesia.
  • Cachexia and Significant Weight Loss: Progressive nutritional decline; weight loss accelerates with advanced tumor burden. Can become severe enough to limit functional independence.
  • Fatigue and Malaise: Profound exhaustion limiting activities of daily living. Constitutional exhaustion reflects advanced systemic disease burden.
  • Night Sweats and Fever: Systemic inflammatory response to advancing malignancy. Fever may also indicate infection.
  • Dysphagia (Difficulty Swallowing): Uncommon late finding from mediastinal involvement.
  • Finger Clubbing: Uncommon and, when present, may reflect a paraneoplastic process.
  • Hoarseness and Laryngeal Involvement: From recurrent laryngeal nerve involvement; may indicate advanced mediastinal disease.
"The progression from nonspecific respiratory symptoms to advanced mesothelioma happens gradually over months to years. Many patients continue working and attributing symptoms to aging or occupational lung disease until breathing becomes severely compromised. By that point, treatment options have been significantly reduced."
— Paul Danziger, Founding Partner, Danziger & De Llano

How Do Symptoms Vary by Cell Type?

The histological subtype of mesothelioma—epithelioid, sarcomatoid, or biphasic—substantially affects the symptom presentation, aggressiveness, and prognosis. These differences have important implications for diagnosis and treatment planning. Guidelines list histological subtype, with performance status and tumour volume, among the main prognostic factors in pleural mesothelioma.[24]

Epithelioid Mesothelioma (Most Common Subtype)

Epithelioid is the most common and least aggressive subtype; it made up 69% of 1,183 patients with stage I-III pleural mesothelioma in SEER (2004-2010).[12] Key characteristics include:

  • Pleural Effusion: Often presents with pleural effusion; the dyspnea-dominant symptom profile reflects effusion-mediated lung restriction.
  • Symptom Onset: Symptoms usually develop gradually over weeks to months.
  • Treatment Response: For unresectable pleural mesothelioma, first-line nivolumab plus ipilimumab is a standard of care, supported by continued overall survival benefit versus chemotherapy at five years in CheckMate 743.[25] Surgery is reserved for carefully selected patients; in the randomised MARS 2 trial, extended pleurectomy decortication plus chemotherapy was associated with worse survival to 2 years than chemotherapy alone.[26] Median survival was 14 months for epithelioid disease in the SEER stage I-III cohort, and 19 months among patients who underwent cancer-directed surgery.[12]
  • Mesothelin Elevation: Mesothelin has good specificity but sub-optimal sensitivity: it is negative in almost half of epithelioid mesotheliomas, especially in the early stages, so it cannot confirm or exclude the diagnosis on its own.[27]
  • Prognosis: The most favourable of the three subtypes, although outcomes vary widely with stage, fitness and treatment.

Sarcomatoid Mesothelioma (Most Aggressive Subtype)

Sarcomatoid mesothelioma is the most aggressive subtype with characteristically poor prognosis; it made up 19% of the SEER stage I-III cohort.[12] Key clinical differences include:

  • Rind-Like Growth Pattern: Tumor may form a solid rind encasing the lung; pleural effusion may be less prominent in some cases.
  • Aggressive Tumor Biology: More prone to chest wall invasion, diaphragmatic involvement, and early metastatic spread. Leads to earlier functional decline.
  • Poor Biomarker Utility: Mesothelin is negative in the sarcomatoid histological subtype, so diagnosis relies on morphology and immunohistochemistry.[27]
  • Response to Treatment: Chemotherapy has limited efficacy in pleural mesothelioma, including sarcomatoid disease.[24] In five-year CheckMate 743 follow-up, nivolumab plus ipilimumab showed continued overall survival benefit versus chemotherapy, and similar benefit was observed regardless of tumor histology.[25]
  • Median Survival: 4 months in the SEER stage I-III cohort (2004-2010), including among patients who underwent surgery.[12]

Biphasic Mesothelioma (Mixed Subtype)

Biphasic tumors contain both epithelioid and sarcomatoid components; they made up 12% of the SEER stage I-III cohort.[12] Under WHO criteria, a pleural mesothelioma resection specimen is classified as biphasic when each component makes up at least 10% of the tumor; in small biopsy specimens, a tumor can be diagnosed as biphasic regardless of the percentage of each component.[28] The proportion of the sarcomatoid component is the major prognostic indicator and treatment driver.[28] Clinical presentation is intermediate:

  • Component-Dependent Prognosis: In an international pathology panel review of 42 biphasic mesotheliomas, a sarcomatoid component of less than 80% correlated with better survival, and a transitional pattern was a poor prognostic indicator.[29] No single percentage threshold is established for predicting an individual's prognosis.
  • Variable Symptom Profile: Presents with intermediate symptom severity; may show both effusion and solid tumor growth patterns.
  • Median Survival: 10 months in the SEER stage I-III cohort (2004-2010), intermediate between epithelioid and sarcomatoid disease.[12]

How Does Peritoneal Mesothelioma Present Differently?

Peritoneal mesothelioma (about 1 in 10 U.S. cases; 11% in national registry data for 2003-2022) arises from the abdominal lining and presents with distinctly different symptoms compared to pleural disease.[3] In a National Cancer Database analysis of 40,488 adults with pleural or peritoneal mesothelioma, peritoneal patients were younger (61.8 vs 73.1 years) and less often male (53.3% vs 77.3%), and had longer median survival (20.9 vs 9.9 months).[30] Understanding these differences is crucial for timely diagnosis and legal documentation.[7]

Peritoneal mesothelioma differs significantly from pleural mesothelioma in demographics, treatment patterns and outcomes.[30] A 2026 study from the University Hospital of Pisa compared 32 epithelioid pleural and 21 epithelioid peritoneal tumors and found different expression of genes involved in extracellular-matrix modification and in NF-κB-mediated inflammatory and angiogenic responses; MMP1, SELE, PAPPA, ESR2 and TNPO2 were upregulated and PKM downregulated in the peritoneal tumors.[31]

Peritoneal Symptoms and Presentation

In a multicenter Italian study of 81 patients, presentation symptoms were ascites, abdominal pain, asthenia, weight loss, anorexia and abdominal mass, in various associations.[16]

  • Abdominal Pain: Persistent, often diffuse abdominal discomfort; may be localized or crampy; can mimic gastroenteritis, irritable bowel syndrome, or other GI disorders. Pain severity varies with disease stage.
  • Ascites (Abdominal Fluid): A common presenting finding; progressive abdominal swelling from malignant fluid accumulation; may cause significant distension and functional impairment. Ascites may be the first radiographic finding prompting investigation.
  • Asthenia (Weakness/Fatigue): Constitutional weakness and tiredness from systemic disease burden. Often attributed to other causes by patients.
  • Weight Loss: Less common in early peritoneal disease but progressive with disease advancement. Often accompanied by anorexia.
  • Anorexia (Loss of Appetite): Reduced appetite and early satiety from ascites and gastric compression. Significantly contributes to weight loss and nutritional decline.
  • Abdominal Mass: Palpable tumor deposits or masses on physical examination. May be detected by imaging studies.
  • Bowel Dysfunction: Nausea, vomiting, diarrhea, or constipation from bowel involvement or irritation. Small bowel obstruction is typically a late manifestation.
⚠ Important: Peritoneal mesothelioma outcomes vary widely, and survival is much shorter for unselected patients. In a non-randomized multi-institutional registry of selected patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), median survival was 53 months and 5-year survival 47%; randomized comparisons are not available. By contrast, median survival for peritoneal mesothelioma in the unselected U.S. National Cancer Database population was 20.9 months.[30][32] Referral to a centre experienced in peritoneal mesothelioma allows assessment for CRS and HIPEC.

Why Peritoneal Is Frequently Misdiagnosed

Peritoneal mesothelioma may be mistaken for:

  • Irritable bowel syndrome (IBS) from gastrointestinal symptoms
  • Ovarian cancer (when presenting in women with ascites; distinguishing morphologically requires specialized immunohistochemistry)
  • Gastric ulcer disease or peptic ulcer disease
  • Hepatic cirrhosis (from ascites)
  • Diverticulitis or appendicitis (from localized pain)
  • Crohn's disease or inflammatory bowel disease
  • Benign ascites from other causes

The insidious abdominal presentation differs markedly from respiratory symptoms of pleural mesothelioma, causing diagnostic delays when clinicians fail to connect abdominal symptoms to asbestos exposure history.

What Are Pericardial and Testicular Mesothelioma Symptoms?

While rare, pericardial and testicular mesothelioma variants present with characteristic symptoms and diagnostic challenges that merit specific attention.

Pericardial Mesothelioma (About 0.2% of Cases)

Pericardial mesothelioma is extraordinarily rare: it accounted for about 0.2% of U.S. mesothelioma cases diagnosed in 2003-2022.[3][33] In Italy's national mesothelioma registry (72 cases diagnosed 1993-2021), the most common clinical presentation was pericardial effusion.[20] Documented symptoms include:

  • Chest Pain: Can occur; nonspecific and may mimic angina or acute coronary syndrome.
  • Shortness of Breath / Dyspnea on Exertion: From pericardial effusion and cardiac compromise.
  • Irregular Heartbeat / Palpitations: Arrhythmias from pericardial irritation or electrical conduction abnormalities.
  • Pericardial Effusion: Leading to cardiac tamponade; can manifest as hypotension, elevated jugular venous pressure, and muffled heart sounds (Beck's triad).
  • Signs of Constrictive Pericarditis: Restrictive physiology limiting cardiac filling.
  • Heart Failure: Progressive right-sided heart failure from pericardial involvement.
  • Cough and Fatigue: General systemic symptoms.

Diagnosis is often delayed; in a pooled analysis of 120 published cases, constrictive pericarditis and diffuse pericardial involvement were associated with worse outcomes.[34] Median overall survival was 2.8 months in the Italian registry.[20] In the pooled analysis of published cases it was 7.4 months, and these estimates come mainly from case reports and small registries.[34]

Testicular Mesothelioma (About 0.2% of Cases)

Mesothelioma of the tunica vaginalis is exceedingly rare. In a 2024 review of 289 published cases, the most common presentations were scrotal or testicular swelling or mass (65%) and hydrocele (55%).[17] Presenting findings include:

  • Hydrocele (Scrotal Swelling): Excess fluid/swelling in the scrotum. Often the first recognized abnormality.
  • Testicular Mass or Lump: Palpable scrotal or testicular mass. May be mistaken for benign cyst or spermatocele.
  • Spermatocele: Benign cyst of epididymis; reported in one of seven patients in a single-institution case series.[35]

Testicular mesothelioma is usually diagnosed in older men but can occur at any age; the average age at the time of diagnosis was 63.6 years in that series of seven patients.[35] Many patients are asymptomatic, and the diagnosis is frequently unsuspected until surgery for another scrotal condition (hernia repair, hydrocele drainage). In SEER data (1973-2015) on 113 patients with testicular mesothelioma, 5-year overall survival was 49% and 10-year overall survival 33%.[36]

Why Is Mesothelioma So Often Misdiagnosed?

No study has established how often mesothelioma is clinically mislabelled (for example as pneumonia, COPD or lung cancer) before a biopsy is taken; symptoms overlap extensively with far more common benign and malignant conditions.[37] For the pathology diagnosis itself, expert-panel review in France's national surveillance programme confirmed the initial pathologist's diagnosis in 67% of cases, ruled it out in 13%, and left it uncertain in the others.[9] In a review of 92 pathological diagnoses at two reference centers in eastern China (2002-2015), the diagnosis was confirmed in 35.3% of pleural and 67.9% of peritoneal tumors.[38] Current guidelines stress that accurate diagnosis depends on adequate pleural biopsy specimens and that decisions be discussed by a multidisciplinary tumor board that includes specialists with mesothelioma expertise.[39]

Common Initial Misdiagnoses

  • Pneumonia or Pleural Effusion: Chest imaging shows fluid around the lung and pleural thickening, mimicking infectious or benign processes. Many patients are treated with antibiotics initially before mesothelioma is considered.
  • COPD/Emphysema: Progressive dyspnea in older males with occupational histories may be attributed to chronic obstructive disease.
  • Lung Cancer (Bronchogenic Carcinoma): Pleural effusion and thickening resemble advanced lung cancer; requires specialized pathology to distinguish. Immunohistochemistry is essential but often delayed.
  • Irritable Bowel Syndrome: Peritoneal mesothelioma's abdominal pain and altered bowel habits initially attributed to functional GI disease.
  • Ovarian or Primary Peritoneal Cancer: Peritoneal mesothelioma in women may be morphologically indistinguishable without immunohistochemical confirmation.
  • Heart Disease or Pericarditis: Pericardial mesothelioma mimics cardiac conditions; often missed until cardiac tamponade develops.
  • Benign Asbestos-Related Pleural Disease: Asbestos plaques and effusions in exposed patients may be wrongly labeled as benign rather than early malignancy.

Root Causes of Misdiagnosis

1. Long Latency Period (often 20 years or more): The exposure history is often decades old. Patients and physicians may not connect symptoms to long-past asbestos exposure; occupational history is frequently not documented in medical records.[40][1]

2. Rarity of Disease: Mesothelioma is rare, so clinical suspicion is often low when it presents with nonspecific symptoms. Physicians practice pattern recognition based on common diagnoses.

3. Nonspecific Symptoms: Dyspnea, cough, and chest pain are caused by dozens of far more common conditions (pneumonia, heart disease, muscle strain). Occam's Razor pushes toward common diagnoses rather than rare malignancy.

4. Pathological Complexity: Diagnosis relies on immunohistochemistry. The International Mesothelioma Interest Group's 2023 pathology guidelines cover immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials, and BAP1 and MTAP immunostains and FISH for homozygous deletion of CDKN2A to distinguish benign from malignant mesothelial proliferations.[41] Samples may be sent to specialized centers for expert review, which can add time.

5. Inadequate Biopsy Samples: Small needle biopsies may yield insufficient tissue for comprehensive immunohistochemistry. Pleural fluid cytology is often negative (mesothelioma sheds cells poorly compared to adenocarcinoma). Repeat biopsy or thoracoscopic sampling may be necessary.

6. Exposure History Not Recognized: Past asbestos exposure is often not recognized or recorded. In the Brazilian tertiary-centre study, only 27 (41%) of the patients had knowledge of prior exposure to asbestos, and knowledge of prior exposure was associated with a shorter time to specialist referral (median 214 vs 120 days).[2]

"Patients are frequently told they have COPD, pneumonia, or heart disease for months or even years before the correct mesothelioma diagnosis is made. By that time, the cancer has advanced significantly, and treatment options have been lost. That diagnostic delay is a critical legal and medical issue."
— Rod De Llano, Founding Partner, Danziger & De Llano

Where Does Research on Blood and Breath Tests for Mesothelioma Stand?

Blood and breath tests for mesothelioma remain research tools, and none has been validated for screening. A 2021 systematic review found no screening tool advocated and no consensus yet on the clinical use of non-invasive diagnostic biomarkers.[15] A 2026 review concluded that single biomarkers like miRNAs, mesothelin and VOCs show promise, but further validation is needed in larger cohorts with correct control groups.[14] Part of the difficulty is that mesothelioma spills little tumor DNA into the bloodstream. In a 2021 study of 14 patients, tumor-specific mutated DNA made up a median of 0.29% of circulating DNA in plasma, compared with 12.75% in pleural fluid, and the authors concluded that mutated DNA is spilled from mesotheliomas mostly into pleural fluid.[42]

FDA-Approved and Established Biomarkers

Mesothelin / Soluble Mesothelin-Related Peptides (SMRP): The MESOMARK assay for SMRP is approved by the FDA under a humanitarian device exemption as a cancer monitoring test for epithelioid and biphasic mesothelioma; it is not a screening test.[43] In a 2012 meta-analysis of individual patient data from 4,491 people, serum mesothelin detected only 32% of stage I or II epithelioid and biphasic mesotheliomas at 95% specificity.[44] In a 2008 prospective study of 538 asbestos-exposed people, SMRP screening produced a high false-positive rate and no subjects were diagnosed with mesothelioma.[45] SMRP is particularly insensitive for sarcomatoid subtypes. The marker is influenced by renal function, age, and BMI, further limiting clinical utility.

Fibulin-3: In a 2012 study, plasma fibulin-3 showed a sensitivity of 96.7% and a specificity of 95.5% for separating patients with and without mesothelioma, and a blinded validation found an area under the curve of 0.87.[46] Later studies were inconsistent: in a 2015 study, plasma fibulin-3 was elevated in mesothelioma patients in one cohort but not in a second, and its diagnostic accuracy was low (63% and 56%).[47] A 2016 meta-analysis of eight studies reported a pooled sensitivity of 0.87 and specificity of 0.89 for blood fibulin-3.[48] A 2017 meta-analysis of seven publications with 468 mesothelioma cases reported a lower pooled sensitivity of 0.62 and specificity of 0.82.[49]

Research-Stage Biomarkers (Not Validated for Screening)

All of the approaches below are experimental; several remain speculative, and none is recommended for screening or early detection.

Circulating microRNA Panels: In a small study published in 2025, plasma samples were collected from 32 asbestos-exposed individuals and 56 patients with pleural mesothelioma, and ratios of plasma microRNAs (miR-24-3p, miR-146a-5p, miR-191-5p, miR-200a-3p, miR-222-3p, miR-223-3p, miR-1260a) differentiated the two groups; the results have not been confirmed in an independent cohort.[50]

Volatile Organic Compound (VOC) Breath Analysis: A 2025 meta-analysis of eight trials with 859 subjects reported a pooled sensitivity of 0.86, pooled specificity of 0.73 and AUC of 0.88 for differentiating mesothelioma patients from healthy controls, with results that varied among trials.[51] Breath tests remain experimental. In an external validation, the original breath-based prediction model performed poorly, with accuracy estimated at only 41%.[52] In the first round of a screening study of 112 asbestos-exposed individuals, 78 were classified by the breath-based model as mesothelioma patients (30% specificity).[53]

Chromosomal Rearrangement Liquid Biopsy (Mayo Clinic 2024): In a study of nine patients with known mesothelioma, tumor whole genome sequencing was used to design personalized chromosomal junction panels, and cell-free junction detection in plasma at follow-up was concordant with disease status.[54] The approach targets chromosomal rearrangements because mesothelioma has few recurring nonsynonymous somatic variants for standard cell-free DNA monitoring.[54]

Pleural Fluid DNA Integrity Index: In a 2012 single-centre study of 75 pleural fluid samples (including 16 mesotheliomas), cytology and pleural fluid DNA integrity index considered together exhibited 81% sensitivity and 87% specificity in distinguishing benign and malignant effusions; it has not been established as a diagnostic test.[55]

Composite Multi-Marker Panels: Researchers are testing panels that combine several markers; none has been validated. In a 2022 study of 26 patients with mesothelioma and 54 healthy subjects with previous asbestos exposure, a panel of mesothelin, fibulin-3 and HMGB1 reached 96% sensitivity and 93% specificity, and further studies are needed to validate it.[56] In a 2025 study of 48 mesothelioma specimens and 42 cases of benign reactive mesothelial hyperplasia, SHOX2 and PTGER4 methylation combined with serum CYFRA21-1 reached a diagnostic sensitivity of 91.3% and specificity of 97.6%.[57] No biomarker panel has yet been adopted in guidelines for diagnosis.

ℹ Emerging (preliminary) evidence: The blood, breath and DNA-based tests described above come from small studies and remain research tools; none is validated or recommended for screening or early detection. SMRP is approved only as an aid to monitoring, not as a routine standard.

How Do Symptoms Progress by Stage?

Pleural mesothelioma is staged with the TNM (Tumor, Node, Metastasis) system. In the eighth edition, the stage groups are stage IA (T1N0), stage IB (T2-3N0), stage II (T1-2N1), stage IIIA (T3N1), stage IIIB (T1-3N2 or any T4) and stage IV (any M1).[58] A ninth-edition TNM classification for pleural mesothelioma has since been published. Prognosis worsens with higher stage overall, although adjacent stage groups overlap. Performance status (ECOG) is assessed separately from stage, and both inform treatment eligibility. Understanding symptom patterns by stage is crucial for both medical management and legal documentation of disease burden.

Stage I: Tumor Confined to the Pleura, No Nodal Spread (T1-3 N0 M0)

  • Presentation: Mild, intermittent dyspnea; slight chest discomfort; small to moderate pleural effusion
  • Symptom Pattern: Often minimally symptomatic
  • Prognosis: The best outcomes among the stage groups; see survival by extent of disease below
  • Treatment Options: If surgical resection is deemed appropriate, it should be part of a multimodal treatment plan, and pleurectomy/decortication (P/D) or extended P/D is strongly favored over extrapleural pneumonectomy (EPP).[39] In the randomised MARS 2 trial of 335 patients, extended pleurectomy decortication plus chemotherapy was associated with worse survival to 2 years than chemotherapy alone.[26] The mesothelioma surgical community has not been unanimous about how to interpret the trial: a published expert perspective, facilitated by Harvey Pass, set out arguments for and against its conclusions, including issues of histologic subtype selection, the timing of randomization and the use of preoperative staging.[59]

Stage II: Ipsilateral Nodal Spread (T1-2 N1 M0)

  • Presentation: Increasing dyspnea; more persistent chest pain; moderate pleural effusion
  • Symptom Pattern: Progressive worsening over weeks; functional limitation begins affecting work and leisure
  • Prognosis: Intermediate; adjacent stage groups overlap
  • Treatment Options: Individualized as for stage I; surgery is considered only for carefully selected patients within multimodal care, and systemic therapy is the basis of treatment for most patients

Stage III: Locally Advanced Disease (IIIA: T3 N1; IIIB: T1-3 N2 or Any T4)

  • Presentation: Significant dyspnea and chest pain; weight loss becomes prominent; possible nerve involvement (hoarseness, Horner syndrome)
  • Symptom Pattern: Large or recurrent pleural effusions requiring therapeutic drainage; systemic symptoms develop
  • Prognosis: Poorer than stage I-II; see the comparison of locally advanced and metastatic disease under stage IV
  • Treatment Options: Usually treated with systemic therapy (immunotherapy or chemotherapy-based regimens), with palliative care integrated alongside. In a phase 3 trial of 440 patients with untreated advanced pleural mesothelioma, adding pembrolizumab to chemotherapy improved median overall survival (17.3 vs 16.1 months with chemotherapy alone).[60]

Stage IV: Distant Metastasis (Any M1)

  • Presentation: Severe dyspnea often at rest; refractory chest pain requiring opioids; severe weight loss and cachexia
  • Symptom Pattern: Profound fatigue; possible dysphagia, superior vena cava obstruction, pericardial involvement with tamponade risk
  • Prognosis: In the international database used to develop the eighth edition, median overall survival was 9.7 months for patients with distant metastasis (cM1) versus 13.4 months for locally advanced (T4 or N3) cM0 disease; individual outcomes vary widely.[58]
  • Treatment Options: Systemic therapy with palliative care integrated alongside. In CheckMate 743, first-line nivolumab plus ipilimumab improved median overall survival versus chemotherapy (18.1 vs 14.1 months) in patients with unresectable pleural mesothelioma.[19] These are medians in a selected trial population, not predictions for an individual.
⚠ Most Mesotheliomas Are Found at an Advanced Stage: Most mesotheliomas are found at an advanced stage because symptoms appear late and are nonspecific. No screening test has been shown to find the disease earlier or to improve survival. The share diagnosed at stage I varies by cohort; about half of patients were stage I in a Spanish hospital that follows asbestos-exposed workers with annual imaging.[6] In SEER data for pleural mesothelioma diagnosed 2015-2021, 5-year relative survival was 23% for localized, 15% for regional and 11% for distant disease (15% for all stages combined). SEER summary stage is not the same as TNM stage, and these are population figures, not predictions for an individual.[22]

Symptom Management and Supportive Care

Palliative and supportive care can be offered alongside anticancer treatment at any stage.[61] ASCO's 2024 guideline recommends that oncology clinicians refer patients with advanced solid tumors to specialized interdisciplinary palliative care teams beginning early in the course of the disease, alongside active treatment of their cancer.[62] In a randomised trial of 174 participants with newly diagnosed pleural mesothelioma, routine early referral to specialist palliative care did not improve health-related quality of life for patients cared for in centres with good access to specialist palliative care when required.[63] The National Cancer Institute's patient treatment guide covers symptom management approaches for mesothelioma, including palliative care options available at all stages of disease.[64] Beyond the medical setting, CancerCare provides free professional support services — including oncology social workers, counseling, and case management — for mesothelioma patients and their families navigating diagnosis, treatment, and caregiving.[65]

Pleural Effusion Management

  • Therapeutic thoracentesis: Draining fluid gives temporary relief; large-volume thoracentesis is used to assess symptomatic response and lung expansion.[66] When fluid returns, pleurodesis or an indwelling pleural catheter is usually considered.
  • Chemical pleurodesis: Either talc poudrage or talc slurry can be used for chemical pleurodesis in symptomatic patients with suspected expandable lung; success depends on whether the lung re-expands.[66]
  • Indwelling pleural catheter (IPC): Enables home-based drainage; guidelines favor an indwelling pleural catheter instead of chemical pleurodesis in patients with nonexpandable lung or failed pleurodesis.[66]
  • Chest tube size: In a randomized trial in patients with malignant pleural effusion, 12F chest tubes were associated with lower pain scores than 24F tubes but higher pleurodesis failure (30% vs 24%), failing to meet noninferiority criteria.[67]

Pain Management

  • Palliative radiotherapy: In a UK phase II trial of 40 patients given 20 Gy in five daily fractions, 14 patients had a clinically meaningful improvement in pain 5 weeks after radiotherapy; there was no improvement in other key symptoms or quality of life.[68]
  • Analgesics: Pain medicines are chosen and adjusted to the type and severity of pain, from non-opioid analgesics to opioids
  • Interventional procedures: Nerve blocks, intercostal nerve blocks for refractory pain

Dyspnea Management

  • Effusion drainage
  • Airflow interventions such as a fan directed at the cheek, and standard supplemental oxygen for patients with hypoxemia[69]
  • Opioids (low-dose morphine for refractory breathlessness)
  • Breathing exercises and pulmonary rehabilitation

Quality of Life Assessment

Two validated instruments are used in mesothelioma clinical trials:

  • LCSS-Meso (Lung Cancer Symptom Scale for Mesothelioma)—mesothelioma-specific quality of life instrument
  • EORTC QLQ-C30—30-item core questionnaire assessing physical, role, cognitive, emotional, and social function

What Should You Do If You Recognize These Symptoms?

Immediate action is critical upon recognizing potential mesothelioma symptoms, particularly in individuals with known or suspected asbestos exposure history.[70]

Red Flag Symptoms Requiring Urgent Medical Evaluation

Seek immediate medical consultation for the following. These are general warning signs; most have common causes other than mesothelioma, but they deserve evaluation, especially after asbestos exposure:

  • Unexplained Progressive Dyspnea: New or worsening shortness of breath not attributable to asthma, heart disease, or common causes
  • Persistent Unilateral Chest Pain: Pain localized to one side of the chest lasting weeks without improvement
  • Unexplained Weight Loss: Weight loss without intentional dieting
  • Persistent Dry Cough: A cough that persists and does not respond to standard treatment
  • Unexplained Pleural Effusion: Fluid around the lungs discovered on chest imaging
  • Abdominal Swelling with Pain: New ascites or progressive abdominal distension combined with pain
  • Scrotal Swelling or Mass: New hydrocele or testicular mass, especially with asbestos exposure history

Critical Actions After Symptom Recognition

1. Document Asbestos Exposure History: Write down dates, workplaces, job duties, and specific products (brand names) involving asbestos. Contact coworkers who can corroborate exposure. This documentation is critical for both medical evaluation and legal claims.

2. Obtain Complete Imaging: Request chest CT scan (not just chest X-ray) if initial evaluation shows pleural effusion. CT detects pleural thickening and enables better staging.

3. Ensure Adequate Biopsy: If pleural effusion is found, ask about diagnostic biopsy. Fluid sampling by thoracentesis alone often cannot confirm mesothelioma; pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy.[24]

4. Discuss Genetic Testing: Ask the care team about germline genetic testing. ASCO's 2025 guideline recommends that all patients with mesothelioma be offered germline testing.[71] European guidance says germline BAP1 testing may be considered in young-onset mesothelioma (under 60) without asbestos exposure.[72]

5. Seek Specialized Evaluation: Ask about referral to a thoracic oncologist or pulmonologist with mesothelioma experience, such as at a specialty treatment center. Therapeutic decisions should be discussed by a multidisciplinary tumor board, including thoracic surgeons with expertise in pleural mesothelioma treatment.[39]

6. Consult Mesothelioma Attorney Immediately: Contact mesothelioma law firms without delay to preserve legal claims. Statute of limitations varies by state but typically ranges from 1-3 years from diagnosis. Early legal consultation ensures comprehensive documentation of exposure and maximizes compensation recovery.

"When a patient presents with respiratory symptoms and a history of asbestos exposure, mesothelioma must be on the differential diagnosis list. Too many physicians reflexively diagnose COPD or pneumonia without considering that patient's occupational history. Patients must be their own advocates and ensure mesothelioma is properly investigated."
— Paul Danziger, Founding Partner, Danziger & De Llano

Delayed mesothelioma diagnosis directly impacts both prognosis and legal recovery. Each month of delay reduces treatment options and potential compensation.

Impact of Diagnostic Delay on Prognosis

  • Stage at Diagnosis: Because of the nonspecific clinical presentation and the absence of validated screening strategies, many cases are diagnosed at an advanced stage.[18]
  • Treatment Options: Most people are diagnosed at an advanced stage, which limits surgical options; systemic treatment remains available. Whether surgery is an option depends on histology, extent of disease, fitness and centre expertise, and randomized data (MARS 2) have not shown a survival benefit from surgery, although experts disagree about how that trial should be interpreted.[59] Stage and performance status can affect eligibility for:
 ** Pleurectomy/decortication (P/D) or extended P/D — considered only for carefully selected patients within multimodal care
 ** Clinical trials requiring good performance status
  • Survival by Extent of Disease: In SEER data for pleural mesothelioma diagnosed 2015-2021, 5-year relative survival was 23% for localized and 11% for distant disease; these are registry summary stages, not TNM stages, and do not predict an individual's outcome.[22]

Documentation for Delayed Diagnosis Claims

  • Obtain all medical records documenting symptom onset date
  • Preserve records of initial misdiagnoses (if any)
  • Document timeline from first symptom to correct diagnosis
  • Collect imaging studies showing disease progression
  • Gather treatment records showing delayed initiation relative to optimal timing
  • Testimony from treating physicians regarding how earlier diagnosis would have changed treatment approach

Get Help Today

Mesothelioma diagnosis requires immediate action on multiple fronts: specialized medical treatment at dedicated mesothelioma centers, aggressive palliative care, and comprehensive legal representation to recover compensation. Delayed action eliminates treatment options and forfeits legal rights through statute of limitations expiration.


Free, Confidential Case Evaluation

Call (855) 699-5441 or visit dandell.com/contact-us

No upfront fees • Experienced representation • National practice


⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Medically reviewed by Dr. Luciano Mutti, MD, PhD — Professor of Oncology, UniCamillus, Rome · Medical Oncology
Last reviewed: 2026-09-30 · Medical review covers clinical accuracy only and is not an endorsement of any legal service. See Editorial Standards for our editorial process.

References

  1. ↑ 1.0 1.1 1.2 1.3 Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34(7):718-21. PMID 1494965.
  2. ↑ 2.0 2.1 2.2 2.3 Mesothelioma in a developing country: a retrospective analysis of the diagnostic process. J Bras Pneumol. 2022;48(5):e20220064. PMID 36000688.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention
  4. ↑ Geographic, Temporal, and Sex-Specific Trends in Mesothelioma Burden in the United States, 1990-2023. JCO Glob Oncol. 2026;12:e2600056. PMID 42275613.
  5. ↑ 5.0 5.1 Mesothelioma Symptoms Guide | Danziger & De Llano
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 Garcia-Prieto F, Pardo SC, Ramírez MTR, et al. Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade. Open Respir Arch. 2024;6(2):100326. PMID 38746541.
  7. ↑ 7.0 7.1 Peritoneal Mesothelioma | Mesothelioma.net
  8. ↑ Mesothelioma Symptoms | Mesothelioma Attorney
  9. ↑ 9.0 9.1 9.2 The French National Mesothelioma Surveillance Program. Occup Environ Med. 2006;63(6):390-5. PMID 16469823.
  10. ↑ Asbestos-Related Diseases | Mesothelioma Lawyer Center
  11. ↑ Malignant Mesothelioma Treatment (PDQ) – Health Professional Version, National Cancer Institute
  12. ↑ 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32. PMID 25791825.
  13. ↑ Chen Z, Gaudino G, Pass HI, et al. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl Lung Cancer Res. 2017;6(3):259-269.
  14. ↑ 14.0 14.1 Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations. Lung Cancer. 2026;212:108893. PMID 41512380.
  15. ↑ 15.0 15.1 Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev. 2021;30(162). PMID 34789461.
  16. ↑ 16.0 16.1 16.2 Manzini VP, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21(2):348-353. PMID 19635740.
  17. ↑ 17.0 17.1 17.2 Mesothelioma of the Tunica Vaginalis Testis: Diagnostic and Therapeutic Management. A Comprehensive Review, 1982-2024., Stella S, Ceresoli GL, Dallari B, et al, Cancers (Basel), 2024. PMID 39682143.
  18. ↑ 18.0 18.1 18.2 Lapidot M, Sattler M. Diagnostic Challenges in Pleural Mesothelioma. Cancers (Basel). 2026;18(9). PMID 42122170.
  19. ↑ 19.0 19.1 Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. PMID 33485464.
  20. ↑ 20.0 20.1 20.2 Pericardial Mesothelioma: Diagnostic and Therapeutic Management, a Population-Based Study in Italy. Cancers (Basel). 2025;17(23). PMID 41375067.
  21. ↑ Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med. 2023;12(11):12208-12220. PMID 37062067.
  22. ↑ 22.0 22.1 22.2 Survival Rates for Pleural Mesothelioma, American Cancer Society
  23. ↑ Pleural Mesothelioma | Mesothelioma.net
  24. ↑ 24.0 24.1 24.2 24.3 ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6). PMID 32451346.
  25. ↑ 25.0 25.1 Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. J Clin Oncol. 2026;44(9):742-749. PMID 41734361.
  26. ↑ 26.0 26.1 Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457-466. PMID 38740044.
  27. ↑ 27.0 27.1 Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013;41(3):706-15. PMID 22835614.
  28. ↑ 28.0 28.1 Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers. Diagnostics (Basel). 2022;12(3):674. PMID 35328227.
  29. ↑ New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. J Thorac Oncol. 2018;13(8):1189-1203. PMID 29723687.
  30. ↑ 30.0 30.1 30.2 Different Diseases, Different Outcomes: A Comparative Study of Peritoneal and Pleural Subtypes. J Surg Res. 2025;312:111-118. PMID 40578061.
  31. ↑ Comparative Gene Expression Analysis of Epithelioid Pleural and Peritoneal Mesothelioma. Cancers (Basel). 2026;18(18):3018. PMID 42794985.
  32. ↑ Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42. PMID 19917862.
  33. ↑ Asbestos Cancer | Mesothelioma Lawyer Center
  34. ↑ 34.0 34.1 Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis. Cancers (Basel). 2026;18(16). PMID 42649897.
  35. ↑ 35.0 35.1 Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health. Clin Genitourin Cancer. 2017;15(5):e871-e875. PMID 28606736.
  36. ↑ Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors. Urology. 2019;126:140-144. PMID 30668959.
  37. ↑ Mesothelioma Diagnosis | Mesothelioma.net
  38. ↑ Improving the Accuracy of Mesothelioma Diagnosis in China. J Thorac Oncol. 2017;12(4):714-723. PMID 28007630.
  39. ↑ 39.0 39.1 39.2 The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma. Ann Thorac Surg. 2026;122(1):3-21. PMID 42019659.
  40. ↑ Asbestos Exposure | Mesothelioma Lawyer Center
  41. ↑ Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024;148(11):1251-1271. PMID 38586983.
  42. ↑ Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. Cancers (Basel). 2021;13(10):2445. PMID 34070018.
  43. ↑ MESOMARK, Humanitarian Device Exemption H060004, U.S. Food and Drug Administration
  44. ↑ Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541-9. PMID 22412141.
  45. ↑ Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med. 2008;178(8):832-7. PMID 18583574.
  46. ↑ Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417-27. PMID 23050525.
  47. ↑ Kirschner MB, Pulford E, Hoda MA, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer. 2015;113(6):963-9. PMID 26263483.
  48. ↑ Ren R, Yin P, Zhang Y, et al. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis. Oncotarget. 2016;7(51):84851-84859. PMID 27769044.
  49. ↑ Pei D, Li Y, Liu X, et al. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis. Oncotarget. 2017;8(8):13030-13038. PMID 28103581.
  50. ↑ Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma. Lung Cancer. 2025;210:108852. PMID 41308209.
  51. ↑ Volatile organic compounds in exhaled human breath for the diagnosis of malignant pleural mesothelioma: a meta-analysis. Front Oncol. 2025;15:1537767. PMID 40502637.
  52. ↑ External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma. Cancers (Basel). 2022;14(13). PMID 35804954.
  53. ↑ Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results. J Breath Res. 2023;17(4). PMID 37683624.
  54. ↑ 54.0 54.1 Individualized Cell-Free DNA Monitoring With Chromosomal Junctions for Mesothelioma. JTO Clin Res Rep. 2024;5(12):100692. PMID 39735890.
  55. ↑ Sriram KB, Relan V, Clarke BE, et al. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer. 2012;12:428. PMID 23009708.
  56. ↑ Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma. Med Lav. 2022;113(6):e2022052. PMID 36475505.
  57. ↑ Combined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma. J Clin Pathol. 2025;78(12):836-842. PMID 39060112.
  58. ↑ 58.0 58.1 The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016;11(12):2112-2119. PMID 27687962.
  59. ↑ 59.0 59.1 A Perspective on the MARS2 Trial. J Thorac Oncol. 2025;20(3):262-272. PMID 39772349.
  60. ↑ Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295-2306. PMID 37931632.
  61. ↑ Peritoneal Mesothelioma | Mesothelioma Attorney
  62. ↑ Sanders JJ, Temin S, Ghoshal A, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2024;42(19):2336-2357. PMID 38748941.
  63. ↑ Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74(4):354-361. PMID 30661019.
  64. ↑ Mesothelioma Treatment (PDQ)—Patient Version, National Cancer Institute
  65. ↑ Mesothelioma Support Services, CancerCare
  66. ↑ 66.0 66.1 66.2 Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline., Feller-Kopman DJ, Reddy CB, DeCamp MM, et al, Am J Respir Crit Care Med, 2018. PMID 30272503.
  67. ↑ Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. JAMA. 2015;314(24):2641-53. PMID 26720026.
  68. ↑ Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. J Thorac Oncol. 2015;10(6):944-50. PMID 25654216.
  69. ↑ Management of Dyspnea in Advanced Cancer: ASCO Guideline. J Clin Oncol. 2021;39(12):1389-1411. PMID 33617290.
  70. ↑ Mesothelioma | Mesothelioma Attorney
  71. ↑ Treatment of Pleural Mesothelioma: ASCO Guideline Update. J Clin Oncol. 2025;43(8):1006-1038. PMID 39778125.
  72. ↑ Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. Eur J Hum Genet. 2023;31(11):1261-1269. PMID 37607989.


Retrieved from "https://wikimesothelioma.com/w/index.php?title=Mesothelioma_Symptoms&oldid=4954"